Login to Your Account



Regeneron's Axokine Positive In Phase II For Obese Diabetics

By Randall Osborne


Tuesday, April 15, 2003
Still sifting data from a Phase III study of its obesity drug Axokine, Regeneron Pharmaceuticals Inc. disclosed preliminary results from a Phase II trial in which the treatment yielded statistically significant weight loss in obese people with diabetes. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription